Juan Gómez Rivas: Recent advances in managing BCR after local treatment for prostate cancer
Juan Gómez Rivas, Urologist, shared an article on X:
“Recent advances in managing biochemical recurrence (BCR) after local treatment for prostate cancer (PCa).
We analyzed 19 studies (9117 patients) to compare different salvage therapies post-radical prostatectomy (RP) or radiation therapy (RT). Results show that combining RT with hormone therapy offers significant improvements in metastatic-free survival (MFS).
Key findings:
- RT + hormone therapy = MFS
- Best RT-based strategy: Prostate bed RT + elective nodal RT + ADT
- Top hormone-based strategy: Enzalutamide + ADT for MFS and OS.
For high-risk BCR or post-RT recurrence, consider adding ARSI (androgen receptor signaling inhibitors) to ADT.
These combinations represent the next step in PCa care, ensuring better outcomes for patients.
Authors: Akihiro Matsukawa , Takafumi Yanagisawa , Tamas Fazekas , Marcin Miszczyk , Ichiro Tsuboi , Mehdi Kardoust Parizi,Ekaterina Laukhtina , Jakob Klemm , Stefano Mancon , Keiichiro Mori , Shoji Kimura , Jun Miki , Juan Gomez Rivas , Timo F W Soeterik , Thomas Zilli , Derya Tilki , Steven Joniau , Takahiro Kimura , Shahrokh F Shariat and Pawel Rajwa.
Source: Juan Gómez Rivas/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023